Gilead’s $1.7B Ouro Buy: Immune System Reset Potential
Gilead Sciences Expands Autoimmune Disease Portfolio with $1.7 Billion Ouro Medicines Acquisition In a significant move to bolster its presence in the rapidly evolving field of autoimmune disease treatment, Gilead Sciences has announced the acquisition of Ouro Medicines, a privately held biotechnology company pioneering novel T cell engager therapies. The deal, valued at $1.7 billion, … Read more